18:24 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

FDA approves Loxo's larotrectinib, second tissue-agnostic approval from agency

FDA granted accelerated approval to Vitrakvi larotrectinib from Loxo Oncology Inc. (NASDAQ:LOXO), making the drug the second tissue-agnostic cancer treatment approved by FDA. Vitrakvi is a small molecule inhibitor of neurotrophic tyrosine kinase receptor 1...
00:13 , Nov 27, 2018 |  BC Extra  |  Company News

FDA approves Loxo's larotrectinib, second tissue-agnostic approval from agency

FDA granted accelerated approval to Vitrakvi larotrectinib from Loxo Oncology Inc. (NASDAQ:LOXO), making the drug the second tissue-agnostic cancer treatment approved by FDA. Vitrakvi is a small molecule inhibitor of neurotrophic tyrosine kinase receptor 1...
19:06 , Oct 26, 2018 |  BC Week In Review  |  Financial News

Ahead of Phase II, TP raises $80M mezzanine round

Oncology company TP Therapeutics Inc. (San Diego, Calif.) raised $80 million in a mezzanine round on Oct. 19 and promoted Athena Countouriotis to CEO from CMO as the company readies to begin a potentially registrational...
12:26 , Oct 19, 2018 |  BC Extra  |  Financial News

Ahead of Phase II, TP raises $80M mezzanine round

Oncology company TP Therapeutics Inc. (San Diego, Calif.) raised $80 million in a mezzanine round and promoted Athena Countouriotis to CEO from CMO as the company readies to begin a potentially registrational Phase II study...
20:32 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Genentech reports ORR of 77.4% for entrectinib in pooled analysis of ROS1-positive NSCLC patients

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported data from an integrated analysis of 53 patients with locally advanced or metastatic c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1)-positive non-small cell lung cancer (NSCLC) in...
17:06 , Aug 23, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling TrkB fusion oncogenes and mutations could help predict sensitivity to the TrkA/TrkB/TrkC inhibitor larotrectinib in patients with blood cancers. Genomic sequencing of 7,311 patients with hematologic malignancies identified one TrkA, one TrkB...
15:55 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain Cell and rat studies identified three TrkA/TrkB/TrkC inhibitors that could help treat pain. Screening of a small molecule library in cell-based activity assays yielded three analogs of a core scaffold -- a piperidine-pyridine...
01:43 , Jun 9, 2018 |  BioCentury  |  Product Development

Past not prologue

Loxo Oncology Inc.’s two-year streak of stunning data at ASCO appears to be the result of good decisions on the back of a healthy dose of luck. But it will be a tall order to...
19:16 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Priority review for Loxo's larotrectinib in tissue-agnostic indication

FDA accepted and granted Priority Review to an NDA for larotrectinib (LOXO-101) from Loxo Oncology Inc. (NASDAQ:LOXO) to treat locally advanced or metastatic solid tumors with neurotrophic tyrosine kinase receptor (Trk) fusion proteins, regardless of...
14:43 , May 29, 2018 |  BC Extra  |  Company News

Priority Review for Loxo's larotrectinib in tissue-agnostic indication

FDA accepted and granted Priority Review to an NDA for larotrectinib (LOXO-101) from Loxo Oncology Inc. (NASDAQ:LOXO) to treat locally advanced or metastatic solid tumors with neurotrophic tyrosine kinase receptor (Trk) fusion proteins, regardless of...